Hansa Biopharma Completes Enrollment in Phase 3 Kidney Transplant Study
Hansa Biopharma AB, known as 'Hansa', has announced the successful completion of enrollment for its significant 20-HMedIdeS-19 Post Authorization Efficacy and Safety (PAES) study, an open-label Phase 3 confirmatory research project. This important clinical trial aims to evaluate the one-year survival of both patients and grafts in individuals undergoing HLA-incompatible kidney transplantation. The enrollment marks progress in treatment options for highly sensitized kidney transplant candidates.
Overview of the PAES Study
The PAES study focuses on patients who have undergone desensitization treatment using imlifidase, the company’s first generation, innovative therapeutic agent that has received conditional approval in Europe for use as a desensitization treatment under the trade name IDEFIRIX. This pivotal study highlights Hansa's commitment to providing access to groundbreaking therapies aimed at improving the lives of patients with complex transplant needs.
Significance of Imlifidase
Imlifidase represents a novel approach in the realm of organ transplantation, particularly for highly sensitized patients. Such patients often face significant hurdles in finding compatible organ donors due to their pre-formed antibodies that react against human leukocyte antigens (HLAs). This can lead to long waiting times for transplants and increased risk of organ rejection.
Expectations for Future Data
Hansa Biopharma is optimistic about the data readout expected in the latter half of 2026 following a thorough follow-up period. The results from the PAES study are anticipated to provide critical information supportive of a submission for full authorization to the European Medicines Agency. COO Søren Tulstrup reiterated the importance of this study in reinforcing treatment access for highly sensitized patients awaiting transplants.
Collaboration and Study Components
The PAES study includes a total of 50 highly sensitized adult kidney transplant patients, complemented by a reference cohort of 64 patients who received transplants without desensitization. This design allows for comparisons across different treatment scenarios and highlights the potential benefits of using imlifidase.
Transformative Impact on Transplantation Care
As quoted by Thomas Lorant, a key investigator in the study, imlifidase’s ability to inactivate donor-specific antibodies allows highly sensitized patients a viable pathway to receive kidney transplants. This creates desired medical opportunities for individuals who were previously sidelined due to their unique immunological profiles. The advancements made through this trial aim to improve not only wait times but also patient survival rates in transplantation.
Understanding Highly Sensitized Patients
Highly sensitized patients make up a notable portion of those on transplant waiting lists. The presence of donor-specific antibodies means that they typically have limited options for successful organ matches. Addressing the needs of these patients is what drives research and study like the PAES, aiming to enhance their chances of receiving transplants.
About Hansa Biopharma
Hansa Biopharma is dedicated to developing life-saving therapies for patients with rare autoimmune conditions. With a robust pipeline built on its proprietary IgG-cleaving enzyme technology, Hansa strives to meet the urgent medical demands faced by patients. The company continues to innovate, exploring additional treatments beyond imlifidase that may improve outcomes for patients with multiple health challenges.
Frequently Asked Questions
What is the purpose of the PAES study?
The PAES study evaluates the one-year patient and graft survival rates in highly sensitized patients following HLA-incompatible kidney transplants after desensitization with imlifidase.
How does imlifidase work in transplantation?
Imlifidase works by cleaving immunoglobulin G (IgG) antibodies, thereby reducing the risk of immune response that could lead to transplant rejection.
What challenges do highly sensitized patients face?
Highly sensitized patients usually face longer waiting times for transplants due to difficulties in finding compatible organ donors, significantly impacting their access to transplantation.
When will the data from the PAES study be available?
The data readout is expected in the second half of 2026, following thorough patient follow-up.
What is Hansa Biopharma's mission?
Hansa Biopharma aims to develop and commercialize effective treatments for rare immune disorders, focusing on unmet medical needs in kidney transplantation and beyond.
